Allan Reine's Insider Trades & SAST Disclosures
Allan Reine's most recent trade in Prime Medicine Inc was a trade of 125,000 Common Stock done at an average price of $1.2 . Disclosure was reported to the exchange on May 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Allan Reine.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Allan Reine | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.18 per share. | 21 May 2025 | 125,000 | 125,000 | - | 1.2 | 147,150 | Common Stock |
| Prime Medicine Inc | Allan Reine | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 2,000,000 | 2,000,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 75,000 | 850,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 275,000 | 275,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2024 | 75,000 | 775,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Foghorn Therapeutics Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Foghorn Therapeutics Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Foghorn Therapeutics Inc | Allan Reine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 09 Aug 2021 | 26,892 | 53,784 | - | 3.7 | 100,038 | Common Stock |
| Foghorn Therapeutics Inc | Allan Reine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 26,892 | 257,512 | - | - | Stock Options (Right to buy) | |
| Foghorn Therapeutics Inc | Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges